1,038,000 Shares in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Purchased by RA Capital Management L.P.

RA Capital Management L.P. bought a new position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 1,038,000 shares of the biotechnology company's stock, valued at approximately $5,968,000. RA Capital Management L.P. owned 4.87% of Enanta Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. bought a new stake in Enanta Pharmaceuticals in the 4th quarter valued at $26,000. Tower Research Capital LLC TRC boosted its stake in shares of Enanta Pharmaceuticals by 46.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 7,202 shares of the biotechnology company's stock valued at $41,000 after purchasing an additional 2,274 shares in the last quarter. Intech Investment Management LLC acquired a new stake in shares of Enanta Pharmaceuticals during the 4th quarter valued at $58,000. Wells Fargo & Company MN increased its stake in shares of Enanta Pharmaceuticals by 69.6% in the fourth quarter. Wells Fargo & Company MN now owns 15,881 shares of the biotechnology company's stock valued at $91,000 after buying an additional 6,518 shares during the period. Finally, Susquehanna Fundamental Investments LLC bought a new position in shares of Enanta Pharmaceuticals during the fourth quarter valued at $105,000. 94.99% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on ENTA shares. StockNews.com raised Enanta Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Wednesday, February 19th. HC Wainwright reissued a "buy" rating and issued a $18.00 price target on shares of Enanta Pharmaceuticals in a research note on Tuesday, February 11th. Finally, JMP Securities restated a "market outperform" rating and issued a $21.00 target price on shares of Enanta Pharmaceuticals in a research note on Tuesday, February 11th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $17.25.

Enanta Pharmaceuticals Stock Down 6.1 %

ENTA stock traded down $0.33 during trading on Tuesday, reaching $5.11. The stock had a trading volume of 143,466 shares, compared to its average volume of 286,070. Enanta Pharmaceuticals, Inc. has a one year low of $4.09 and a one year high of $17.24. The company's 50 day moving average is $5.86 and its two-hundred day moving average is $7.01. The company has a market capitalization of $109.01 million, a price-to-earnings ratio of -1.03 and a beta of 0.81.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last released its quarterly earnings data on Monday, February 10th. The biotechnology company reported ($1.05) EPS for the quarter, beating the consensus estimate of ($1.16) by $0.11. Enanta Pharmaceuticals had a negative net margin of 157.57% and a negative return on equity of 75.53%. As a group, research analysts predict that Enanta Pharmaceuticals, Inc. will post -4.65 earnings per share for the current fiscal year.

Insider Activity at Enanta Pharmaceuticals

In other news, CEO Jay R. Luly bought 45,000 shares of Enanta Pharmaceuticals stock in a transaction that occurred on Wednesday, February 12th. The shares were acquired at an average price of $5.69 per share, with a total value of $256,050.00. Following the completion of the purchase, the chief executive officer now directly owns 846,638 shares in the company, valued at $4,817,370.22. The trade was a 5.61 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. 13.89% of the stock is owned by corporate insiders.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.